Type five lines to get your key investment message across here. Explain to the investor why this company has a strong product or service and what its competitive advantage is. Is the stock cheap or expensive relative to history or peer group?
Written by
Vermilion Energy |
Q418 results X% ahead/below of consensus |
FY18 results |
Oil & gas |
27 February 2019 |
Share price performance
Business description
Next events
Analysts
is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
Type five lines to get your key investment message across here. Explain to the investor why this company has a strong product or service and what its competitive advantage is. Is the stock cheap or expensive relative to history or peer group?
Year end |
Revenue (C$m) |
EBITDA* (C$m) |
Operating cash flow (C$m) |
Net (debt)/ cash** (C$m) |
Capex ex acquisitions (C$m) |
Yield |
12/16 |
828.5 |
361.7 |
509.5 |
(1298.9) |
242.4 |
4.5 |
12/17 |
1024.4 |
673.5 |
593.9 |
(1223.8) |
320.4 |
5.7 |
12/18 |
1534.6 |
693.2 |
876.0 |
(1706.2) |
504.4 |
8.1 |
12/19e |
1856.6 |
1169.9 |
1076.0 |
(1593.8) |
527.6 |
8.2 |
Note: *Reported EBITDA includes hedging and FX gains/losses. **Net debt = long-term debt, short-term debt minus cash and equivalents.
[Click here to add your first conclusion title]
Type your conclusion here. By the time you write the front page, you should have a clear idea of the main conclusions and express them in concise active language. Expand on your message. Be concise and expand on the key message within the research note.
[Click here to add your second conclusion title]
Possibly consider sensitivities to your view on the company, both on the upside and the downside.
Valuation: [Click here to add your valuation title]
This is the last point that you are expanding on. Refer to the company valuation. Where is the company trading? Has the rating improved or declined relative to the company’s own share price history? How does it look against peers?
Results versus Edison and company consensus
Exhibit 1: Q418 and FY18 results vs Edison forecasts and consensus
Metric |
Unit |
Edison |
Consensus |
Reported |
vs Edsion |
vs consensus |
Q418 |
|
|||||
Production |
kboed |
98.9 |
100.4 |
|
||
FFO |
C$m |
222.2 |
208.3 |
|
||
FFO/share (dil) |
C$/share |
1.4 |
1.4 |
|
||
|
|
|||||
|
|
|||||
|
|
|||||
2018 |
|
|||||
Production |
kboed |
86.5 |
86.9 |
|
||
FFO |
C$m |
833.4 |
818.8 |
|
||
FFO/share (dil) |
C$/share |
5.8 |
5.8 |
|
||
Net debt |
C$m |
1716.2 |
1948.4 |
|
|
|
Source: Edison Investment Research, Vermilion Energy
|
|
Research: Healthcare
BioPorto has reported revenue of DKK26.0m for 2018. The company’s main strategic objective is the development and approval of The NGAL Test, but its ongoing sales of research products provide insight into future markets for the test. In particular, the company reported DKK9.2m in sales of the test for research purposes, an increase of 41% globally and 80% in the US. This demonstrates increased traction and appreciation of NGAL as an important biomarker for acute kidney injury (AKI).